BR112012017979A2 - formulações líquidas para conjugado de g-csf ação prolongada - Google Patents

formulações líquidas para conjugado de g-csf ação prolongada

Info

Publication number
BR112012017979A2
BR112012017979A2 BR112012017979A BR112012017979A BR112012017979A2 BR 112012017979 A2 BR112012017979 A2 BR 112012017979A2 BR 112012017979 A BR112012017979 A BR 112012017979A BR 112012017979 A BR112012017979 A BR 112012017979A BR 112012017979 A2 BR112012017979 A2 BR 112012017979A2
Authority
BR
Brazil
Prior art keywords
csf
liquid formulation
prolonged action
liquid formulations
conjugated
Prior art date
Application number
BR112012017979A
Other languages
English (en)
Other versions
BR112012017979B1 (pt
Inventor
Byung Sun Lee
Jae Min Lee
Mi Ji Lee
Se Chang Kwon
Sung Min Bae
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44307381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017979(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of BR112012017979A2 publication Critical patent/BR112012017979A2/pt
Publication of BR112012017979B1 publication Critical patent/BR112012017979B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

formulação líquida para ação prolongada de g-csf conjugado. é divulgada uma formulação líquida que permite ação prolongada de g-csf conjugados, que têm melhorado a duração in vivo e a estabilidade, para ser estável quando armazenado durante um longo período de tempo. isto compreende uma composição estabilizada caracterizada por tampão e manitol. sendo livre de albumina de soro humano e de outros fatores potencialmente prejudiciais para o corpo, a formulação líquida é livre de preocupações sobre infecções virais e garante a estabilidade de armazenamento excelente para ação prolongada de g-csf conjugados.
BR112012017979-9A 2010-01-19 2011-01-18 Formulações líquidas para conjugado de g-csf de ação prolongada BR112012017979B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0004839 2010-01-19
KR20100004839 2010-01-19
PCT/KR2011/000369 WO2011090305A2 (en) 2010-01-19 2011-01-18 Liquid formulations for long-acting g-csf conjugate

Publications (2)

Publication Number Publication Date
BR112012017979A2 true BR112012017979A2 (pt) 2016-05-03
BR112012017979B1 BR112012017979B1 (pt) 2021-10-13

Family

ID=44307381

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017979-9A BR112012017979B1 (pt) 2010-01-19 2011-01-18 Formulações líquidas para conjugado de g-csf de ação prolongada

Country Status (17)

Country Link
US (1) US9867777B2 (pt)
EP (1) EP2525787B1 (pt)
JP (2) JP5657698B2 (pt)
KR (1) KR101340710B1 (pt)
CN (2) CN107412737A (pt)
AR (1) AR080427A1 (pt)
AU (1) AU2011207915B2 (pt)
BR (1) BR112012017979B1 (pt)
CA (1) CA2787648C (pt)
ES (1) ES2654102T3 (pt)
HK (1) HK1246190A1 (pt)
HU (1) HUE034398T2 (pt)
MX (1) MX340463B (pt)
PT (1) PT2525787T (pt)
RU (1) RU2519031C1 (pt)
TW (1) TWI409082B (pt)
WO (1) WO2011090305A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340463B (es) 2010-01-19 2016-07-06 Hanmi Science Co Ltd * Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
DK2945745T3 (da) * 2013-01-19 2022-04-25 Fluicell Ab Fremgangsmåder til fremstilling, ændring, fjernelse og anvendelse af væskemembraner
JP6294868B2 (ja) * 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
CA2919583C (en) 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
WO2015152618A1 (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
DK3134127T3 (da) 2014-04-25 2020-03-16 Rinat Neuroscience Corp Antistoflægemiddelkonjugater med høj lægemiddelladning
WO2017047385A1 (ja) 2015-09-14 2017-03-23 大王製紙株式会社 紙管及び当該紙管を使用したロール状シート
CN105311625A (zh) * 2015-11-23 2016-02-10 哈药集团生物工程有限公司 一种含有重组人粒细胞刺激因子的药物组合物
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
KR102461760B1 (ko) * 2017-10-11 2022-10-31 엘랑코 유에스 인코포레이티드 돼지 g-csf 변이체 및 그 용도
EA202092623A1 (ru) * 2018-05-04 2021-02-01 Илькоген Илач Санайи Ве Тиджарет А.Ш. СТАБИЛЬНЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
BR112021015428A2 (pt) 2019-02-13 2022-02-15 Ilkogen Ilac Sanayi Ve Ticaret A S Uma fc híbrida de fusão g-csf para prevenir neutropenia ou reduzir a duração da neutropenia
DK3744319T3 (da) * 2019-05-28 2023-01-16 Ilkogen Ilac Sanayi Ve Ticaret A S Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63992B1 (en) 1985-09-17 1995-06-28 Chugai Pharmaceutical Co Ltd Human granulocyte colony stimulating factor
KR910005624B1 (ko) 1985-09-17 1991-08-01 쥬우가이 세이야꾸 가부시끼가이샤 인체 과립성 백혈구의 콜로니 자극 인자 활성을 갖는 당단백질의 제조방법
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
NZ295673A (en) 1994-11-01 1999-03-29 Wels Wilfried Nucleic acid transfer system using recombinant multi-domain proteins each domain having a different function
EP0859843A1 (en) 1995-10-05 1998-08-26 G.D. Searle & Co. Novel g-csf receptor agonists
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR19990009888A (ko) * 1997-07-12 1999-02-05 성재갑 콜로니 자극 인자의 안정한 용액 제형
AU749815B2 (en) 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
JP4454571B2 (ja) 1998-03-06 2010-04-21 中外製薬株式会社 蛋白非添加製剤
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
WO2006097944A2 (en) 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
KR20060108040A (ko) * 2005-04-12 2006-10-17 주식회사 엘지생명과학 인 과립구 콜로니 자극인자 용액 제형
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
EP2175834B8 (en) * 2007-07-10 2012-08-22 Eli Lilly And Company Glp-1-fc fusion protein formulation
BRPI0815975B8 (pt) * 2007-08-27 2021-05-25 Biogenerix Ag preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa
KR101061105B1 (ko) 2008-03-10 2011-08-31 디아이씨 가부시끼가이샤 철 착체를 촉매로 하는 중합체의 제조 방법
MX340463B (es) 2010-01-19 2016-07-06 Hanmi Science Co Ltd * Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법

Also Published As

Publication number Publication date
AU2011207915A1 (en) 2012-08-23
CN102740840A (zh) 2012-10-17
HUE034398T2 (en) 2018-02-28
JP2014224151A (ja) 2014-12-04
JP5657698B2 (ja) 2015-01-21
AU2011207915B2 (en) 2013-07-11
WO2011090305A3 (en) 2011-11-10
CA2787648A1 (en) 2011-07-28
EP2525787B1 (en) 2017-03-15
JP2013517324A (ja) 2013-05-16
EP2525787A4 (en) 2014-07-02
EP2525787A2 (en) 2012-11-28
CA2787648C (en) 2014-10-07
KR101340710B1 (ko) 2013-12-12
WO2011090305A2 (en) 2011-07-28
ES2654102T3 (es) 2018-02-12
MX2012008454A (es) 2012-11-06
CN107412737A (zh) 2017-12-01
BR112012017979B1 (pt) 2021-10-13
HK1246190A1 (zh) 2018-09-07
PT2525787T (pt) 2017-12-18
KR20110085917A (ko) 2011-07-27
US20120294829A1 (en) 2012-11-22
AR080427A1 (es) 2012-04-11
TW201129387A (en) 2011-09-01
TWI409082B (zh) 2013-09-21
RU2519031C1 (ru) 2014-06-10
US9867777B2 (en) 2018-01-16
MX340463B (es) 2016-07-06

Similar Documents

Publication Publication Date Title
BR112012017979A2 (pt) formulações líquidas para conjugado de g-csf ação prolongada
BR112012017982A2 (pt) formulações líquidas para conjugado de eritropoietina de longa ação
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
UY30190A1 (es) Profarmacos mejorados de analogos de cc-1065
IN2014CN02591A (pt)
CO7151500A2 (es) Preparación inyectable
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
CO6680640A2 (es) Uso de aglutinantes para fabircar formulaciones estables al almacenamiento
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
JP2012520342A5 (pt)
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
AR106776A1 (es) Composiciones de cuidado oral
AR059113A1 (es) Composicion para administracion topica
FR2968950B1 (fr) Composition cosmetique comprenant un compose d'acide cucurbique
AR083769A1 (es) Formulaciones orales que comprenden polietilenglicol
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
NI201100201A (es) Metodo y composición para el control de parásitos
BR112015014433A2 (pt) compostos tricíclicos
MX2015007424A (es) Composiciones y/o articulos con solubilidad mejorada de un activo solido.
EP2421529A4 (en) SUNSHORE-CONJUGATED IMMUNOGENIC COMPOSITIONS AND VACCINES
AR050101A1 (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/01/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.